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Background. Several lines of evidence point to the 12-
lipoxygenase (12-LOX) family as important mediators in hyper-
tension, diabetes, and other cardiovascular diseases. The kidney
has been a main focus for research of the role of this pathway in
several disease models. While most of the studies have focused
on mesangial or vascular cells, less is known about 12-LOX
regulation at the renal tubular level. The aim of the study was
to characterize the expression and regulation by hormones of
the family of 12-LOX in mouse distal convoluted tubule at the
molecular level.
Methods. An immortalized mouse distal convoluted tubule
(mDCT) cell line was used. mRNA and protein levels were
assessed by reverse transcription-polymerase chain reaction
(RT-PCR) and Western blot, respectively, while 12(S)-HETE
production was evaluated by enzyme-linked immunosorbent
assay (ELISA). Cells were challenged with aldosterone, an-
giotensin II, 8Br-cAMP, and vasopressin.
Results. We showed that both platelet (P) and leukocyte (L)-
type 12-LOX are expressed in the mDCT cell line, as well as
in distal tubules of human kidneys. The production of 12(S)-
HETE by mDCT cells was increased in response to cAMP
(by two-fold) and by vasopressin (by 1.5-fold). In contrast, nei-
ther aldosterone nor angiotensin II exerted appreciable effects
on 12(S)-HETE production. The mRNA and protein levels of
P-12LOX and L-12LOX were not changed by the different hor-
mones, suggesting that they may act by modulating enzyme ac-
tivity. We further have demonstrated that this mDCT cell line
also expressed the recently cloned 12(R)-LOX.
Conclusion. mDCT cells show an active 12-LOX metabolism
that appears to be modulated by cAMP and vasopressin.
Lipoxygenases (LOX) constitute a family of lipid per-
oxidizing enzymes that oxygenate free and esterified
polyenolic fatty acids to the corresponding hydroper-
oxy derivates. Mammalian LOX metabolism produces
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a series of bioactive compounds, such as leukotrienes,
lipoxins, hydroxyeicosatetraenoic acids, and hepoxilins,
which play an important role as molecules involved in the
control of vasoconstriction, bronchoconstriction, blood
clotting, as well as granulocyte chemotaxis and other in-
flammatory reactions (for review see references [1, 2]).
The LOX enzymes are named according to the specific
carbon atoms of arachidonic acid to be oxygenated, and
5-, 8-, 12-, and 15-LOX have been found to be expressed
in mammalian tissues. In this sense, 12-lipoxygenases
(12-LOX) catalyze the transformation of arachidonic
acid to 12(S)-hidroperoxyeicosatetranoic acid (12(S)-
HPETE), which is reduced by different mechanisms
to 12(S)-hidroxyeicosatetranoic acid (12-(S)HETE). The
12-LOX subfamily includes 3 different isoforms: platelet
type [3], leukocyte type [4], and epidermal type [5]. A new
mammalian 12-LOX originally cloned from skin that gen-
erates products with R-chirality (12(R)-HETE) has also
been described [6].
A number of cardiovascular biological activities have
been reported for 12(S)-HETE and 12(R)-HETE. In this
sense, both metabolites act as vasoconstrictors in small
renal arteries [7]. Moreover, 12(S)-HETE also partici-
pates in the modulation of angiotensin II–induced al-
dosterone secretion [8], and in angiotensin II–induced
intracellular calcium transients in cultured rat vascular
smooth muscle cells [9]. It has been reported that platelet
12(S)-HETE production is enhanced in the sponta-
neously hypertensive rat [10]. According to this find-
ing, we recently described that 12(S)-HETE levels and
platelet 12-LOX protein were increased in patients with
essential hypertension [11]. On the other hand, 12-(S)-
HETE produced by mesangial cells and podocytes in
response to hyperglycemia has been found to play an im-
portant role in the development of diabetic nephropathy
[12, 13].
While 12-HETE metabolism has been well character-
ized in vascular smooth muscle and mesangial cells, less
information is available regarding renal tubular regula-
tion of this pathway. Renal tubules are relevant in the
pathogenesis of hypertension, since disturbances in the
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regulation of Na excretion are the common pathway in
both Mendelian and polygenic forms of hypertension
[14]. To date, 12-HETE metabolism has been found and
characterized, albeit not at the molecular level, only in
proximal tubular preparations [15, 16]. However, the fine
and regulated control of Na excretion resides in the distal
nephron, where most of the research on candidate genes
or pathways for hypertension has been taken [14]. Pre-
vious studies have reported the expression of 12-LOX in
rat distal tubules [12]. Because very little is known about
the 12-LOX metabolism in distal nephron, the aim of
this study was to characterize at the molecular level the
expression and the hormonal regulation of different 12-
LOX isoforms in a mouse distal convoluted tubule cell
model (mDCT).
METHODS
Cell culture
Distal convoluted tubule cells were kindly provided to
us by Dr. Peter A. Friedman (University of Pittsburgh,
PA). They were previously isolated and immortal-
ized from mice by Pizzonia et al [17], and function-
ally characterized by Friedman and Gesek [18]. Cells
were grown on 60-mm dishes (Techno Plastic Prod-
ucts, Trasadingen, Switzerland) in Dulbecco’s modified
Eagle’s medium/Ham’s F-12 media (1:1) (Sigma-Aldrich,
St. Louis, MO, USA) supplemented with 5% heat-
inactivated fetal calf serum (Sigma-Aldrich), 2 mmol/L
L-glutamine (Gibco BRL, Paisley, UK), 0.5 lg/mL strep-
tomycin, 0.5 lg/mL penicillin, and 1 lg/mL neomycin
(Gibco BRL) in a humidified atmosphere of 5% CO2-
95% air at 37◦C.
To examine the hormonal treatment effects, cells were
cultured to confluence, and monolayers were transferred
to serum-free media for 24 hours. The monolayers were
then subsequently placed in either serum-free media
supplemented with 1 lmol/L aldosterone, 0.5 mmol/L
8-Br-cAMP, 100 nmol/L angiotensin II, and 10 nmol/L
arginine vasopressin (AVP; Sigma-Aldrich). Serum-free
media with 0.032% ethanol was used as vehicle control.
It should be mentioned that both mineralocorticoid and
glucocorticoid receptors were expected to be activated
with the concentration of aldosterone used, and that these
cells have been described before as arginine vasopressin
sensitive [19, 20].
Immunohistochemistry
Human kidney samples obtained from nephrec-
tomy specimens caused by cancer were fixed with 4%
paraformaldehyde in phosphate-buffered saline (PBS)
overnight and embedded in paraffin. Immunohisto-
chemistry was performed using the automatic system
Techmate 500 and the EnVision system (Dako, Carpin-
teria, CA, USA). Sections (4 lm) from unaffected tissue
were deparaffinized and rehydrated through xylene and
alcohol. Endogenous peroxidases were blocked with per-
oxidase blocking reagent (ChemMate; Dako) for 7.5 min-
utes. L-12LOX and P-12LOX serums were used at 1/20
and 1/100, respectively, for 30 minutes at room temper-
ature. The samples were washed then with ChemMate
solution, and subsequently incubated for 30 minutes at
room temperature with the horseradish peroxidase sec-
ondary antibody (Dako). Slides were washed, and the
immune reaction was visualized using diaminobenzidine.
Sections were lightly counterstained with hematoxylin,
followed by dehydration and coverslip mounting. Nega-
tive controls were performed replacing the primary anti-
body with PBS.
RNA isolation and RT-PCR
Confluent cells were washed 3 times with 3 mL of
PBS, and total RNA was then carefully extracted using
1 mL of TRIzol Reagent (Gibco BRL). An aliquot was
treated with DNA-freeTM (Ambion, Austin, TX, USA)
for elimination of the potential contaminating DNA from
RNA preparations. RNA concentration was then de-
termined spectrophotometrically by ultraviolet absorp-
tion at 260 nm, and 2 lg was resolved by denaturing
(formamide/formaldehyde) agarose gel electrophoresis
to inspect for degradation.
For reverse transcription (RT), 2.5 lg of total RNA
was transcribed using AMV-cDNA synthesis kit (Roche
Molecular Biochem, Indianapolis, IN, USA). cDNA syn-
thesis was carried out in a PTC-200 DNA Engine (MJ
Research, Waltham, MA, USA) for 1 hour at 42◦C, and
stopped by heating at 95◦C for 5 minutes. RT reagents
were checked for amplicon contamination by the inclu-
sion of a control without RNA. Different polymerase
chain reactions (PCR) were performed using specific
mouse or rat primers (see Table 1), and were con-
ducted in 25 lL containing 20 mmol/L Tris-HCl (pH 8.4),
50 mmol/L KCl 1.1 to 1.9 mmol/L of MgCl2, 200 lmol/L
dNTPs, 0.8 lmol/L of each primer, 1U Taq polymerase
(Roche Molecular Biochem), and 1.5 lL of cDNA.
Mouse and rat isoenzyme-specific 12-LOX primers were
described by Heidt et al [21] and Kawajiri et al [22]. Each
PCR was within the linear range of amplification.
Protein isolation and Western blot analysis
mDCT cells were washed twice with cold PBS and
scraped with 2 mL of PBS. Cells were transferred to a
clean tube and centrifuged at 1000g for 5 minutes. Su-
pernatant was removed and cells were homogenized in
500 lL ice-cold homogenization buffer [0.32 mol/L su-
crose, 5 mmol/L Tris-HCl (pH 7.5), and 2 mmol/L EDTA]
plus protease inhibitors (2 mmol/L Pefabloc SC and 70 lL
Complete Protease inhibitor ×7; Roche Molecular
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Table 1. Primer sequences for RT-PCR
Amplicon
Primer Sequence 5′→3′ size bp No. cyclesa
SGK-1 forward CTCCGCCAAGTCCCTCTCAACAAAT 644 26
SGK-1 reverse CTCATACAGGACAGCCCCAAGACAC
E-12LOX forward TGCCCATCTCAGCCCCAGAGGA 200 30
E -12LOX reverse AGAAGTGGGTACTAGGGATTCA
L-12LOX forward TTCCAAGAGCCGCTTTCCATA 259 32
L- 12LOX reverse TCTATCACTAGCCCAAAACATC
P-12LOX forward TACCTCAAGCCCAGCCGCATAG 197 28
P-12LOX reverse CAAGACATTTAGTGCCCTGTAG
12(R) LOX forward ACCGATGCAGACCAAGGGGCTAAC 333 32
12(R) LOX reverse CAGTGTATGGAGGGGAGGGCAGAA
AT1a forward GCATCATCTTTGTGGTGGG 690 35
AT1a reverse ATCAGCACATCCAGGAATG
GAPDH forward AATGCATCCTGCACCACCAA 513 27
GAPDH reverse GTAGCCATATTCATTGTCATA
aAll PCRs, except AT1a, were performed within the linear range of amplification.
Biochem). The cell lysate, termed homogenate, was
stirred at 4◦C with 0.25% of sodium dodecyl sulfate (SDS)
for 1 hour. Protein content of all samples was deter-
mined using the Bio Rad (Hercules, CA, USA) protein
assay based on the Bradford method, with bovine serum
albumin (BSA) as a standard [23]. Protein (50 lg) of
the subcellular fractions was denatured in SDS-sample
lysis buffer [2% SDS, 62.5 mmol/L Tris-HCl (pH 6.8),
30% glycerol, 5% b-mercaptoethanol, and 0.1% bro-
mophenol blue] by boiling for 5 minutes. Samples were
then subjected to SDS-PAGE on 7.5% polyacrylamide
gels before electrophoretic transfer to polyvinylidene flu-
oride (PVDF) membrane (ImmobilonTM-P; Millipore,
CA, USA). Preliminary 7.5% SDS-polyacrylamide gels
were run, and were stained with Coomassie blue to
confirm equality of loading in each lane. After the
PVDF membranes were blocked with 3% milk in TBS
(150 mmol/L NaCl and 10 mmol/L Tris) with 0.1%
Tween-20 for 60 minutes, membranes were incubated
with a 1:1000 final dilution of rabbit polyclonal antiserum
against human P-12LOX antiserum (Oxford Biomedical,
Oxford, MI, USA) or pig L-12LOX antiserum (kindly
provided by Dr. Natarajan) for 60 minutes. The immuno-
complexes were detected by binding with 1:4000 diluted
secondary antibody (horseradish peroxidase–conjugated
goat antirabbit IgG; Amersham, Piscataway, NJ, USA)
using the enhanced chemiluminescence method (ECL,
Amersham). The blots were quantified by densitome-
try (Non Linear Dynamics, Ltd., Newcastle upon Tyne,
UK). Densitometry values are expressed in arbitrary
units.
Determination of 12-(S)HETE and TGF-b levels
mDCT cells were serum depleted 24 hours before each
experiment. Cells were then treated with 1 lmol/L aldos-
terone, 0.5 mmol/L 8-Br-cAMP, 100 nmol/L angiotensin
II, and 10 nmol/L AVP or 0.032% ethanol (used as vehi-
cle) for 2 hours or 6 hours. At the end of the incubation
period, the culture dishes were placed on ice, and the
supernatants were removed and saved at −80◦C. Su-
pernatants were evaporated with SpeedVac-System
AES2010 (Savant, New York, NY, USA), and the residue
was rediluted with 250 lL of ice-cold electroimmunoas-
say (EIA) phosphate buffer containing 0.01 mol/L phos-
phate, 0.9% NaCl, 0.1% MgCl2, 0.1% BSA, and 0.1%
sodium azide at pH 7.4. 12(S)-HETE was determined
by enzyme-linked immunosorbent assay (ELISA; DRG
Diagnostics, Marburg, Germany). The 12-HETE ELISA
is specific for 12(S)-HETE, with <2.5% cross-reactivity
with 12(R)-HETE, 0.3% with 15-HETE, 0.2 with 5-
HETE, 0.1% with PGE2, and 0.1% with PGI2. Signal
was analyzed with spectrofluorimeter spectraMax-340
(Molecular Devices Corp., Wokingham, UK) at 405 nm
coupled with softMax-Pro 1.2.1. The level of TGF-b1 pro-
duction in cell culture was determined by using a commer-
cially available enzyme immunoassay kit (Quantykine;
R&D Systems, Minneapolis, MN, USA). Briefly, cell cul-
ture medium with or without angiotensin II activation
was isolated and stored at −70◦C until the assay was per-
formed. To activate latent TGF-b1 into immunoreactive
TGF-b1 detectable by the immunoassay test, we acidi-
fied the samples (to 0.1-mL sample, add 0.1 mL of 2.5 N
acetic acid/10 mol/L urea), and then neutralized (adding
0.1 mL of 2.7 N NaOH/1 mol/L HEPES) to yield a pH
of 7.2 to 7.6. Three sample dilutions (1:12, 1:24, and 1:48)
were performed with the calibrator Diluent RD6M. TGF-
b1 was determined using a solid phase TGF-b1–specific
sandwich ELISA (Quantykine; R&D Systems).
Statistical analysis
Data are presented as mean ± standard error of
the mean (SEM). Comparisons between means were
determined by two-sided Mann-Whitney U test for un-
paired data. The 5% probability level was regarded as
significant.
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Fig. 1. Effect of aldosterone (ALDO) and
8Br-cAMP on mouse distal convoluted tubule
(mDCT) cells. (A) Expression levels of serum
and glucocorticoid-induced kinase 1 (sgk1)
mRNA in response to different stimuli at
3 hours. GAPDH was amplified to standardize
for the amount of RNA subjected to reverse
transcription. Values are mean ± SEM (N =
6 different cultures) of densitometry arbitrary
units. ∗∗P ≤ 0.01 vs. vehicle. A representa-
tive gel with sgk1 band (upper) and GAPDH
housekeeping band (lower) is shown. (B) RT-
PCR with specific primers (Table 1) against
11b hydroxysteroid dehydrogenase type 2
(11bHSD2), the mineralocorticoid receptor
(MR), the glucocorticoid receptor (GR), and
the angiotensin II receptor (AT1a) was per-
formed with total RNA of mouse kidney as
positive control (C+), while PCR tube with-
out cDNA was performed in each reaction
to discard environmental contamination of
PCR reaction (C−). Specific bands were ob-
tained, purified, and sequenced to confirm
their identity.
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Fig. 2. Expression of 12-lipoxygenase (12-
LOX) isoforms in vivo and in vitro. (A)
Leukocyte-type 12LOX (L-12LOX) expres-
sion in different mouse tissues (upper panel),
and in mouse distal convoluted tubule
(mDCT) cells (lower panel). The middle
panel shows an immunohistochemical stain-
ing of human kidney (magnification 200×).
The arrows indicate distal tubules. (B) Platelet
type 12LOX (P-12LOX) expression in dif-
ferent mouse tissues (upper panel) and in
mDCT cells (lower panel). The middle panel
shows an immunohistochemical staining of
human kidney (magnification 200×). The ar-
rows show distal tubules. Bl, PCR blank; C−,
RT-negative control; PEN, endocrine pan-
creas; PEX, exocrine pancreas; Fibr, fibrob-
laots; Duod, duodenum.
RESULTS
Expression and regulation of the serum and
glucorticoid-induced kinase 1 (sgk1)
Aldosterone and cAMP sensitivity of the mDCT cell
line has been previously evaluated by our group [20].
As previously demonstrated, mDCT cells express both
mineralo- and glucocorticoid receptors, as well as the
enzyme 11bHSD2, pointing out to the presence of
aldosterone-response machinery (Fig. 1B). In addition,
Figure 1A shows the expression level of the aldosterone-
induced gene sgk1 mRNA by using a semiquantita-
tive RT-PCR. Sgk1 was stimulated by ALDO and
8Br-cAMP within 1 hour of treatment, and reached a
peak at 3 hours [vehicle 0.93 ± 0.06, ALDO 1.57 ± 0.09,
8Br-cAMP 1.71 ± 0.14, and combined treatment 1.92 ±
0.10 (P ≤ 0.01 vs. vehicle)]. Sgk1 levels decreased with
time, but were still significantly higher up to 24 hours
after treatments (data not shown). As positive control,
mouse kidney RNA was used. The identity of the bands
was confirmed by the sequencing method. Figure 1B also
shows the expression of the AT1a receptor in mDCT cells.
On the contrary, we did not detect the expression of the
AT1b or AT2 angiotensin II receptors (not shown).
Renal 12-LOX distribution in vivo
As shown in Figure 2, 12-LOX was widely distributed in
mice tissues, as reported previously [21]. Figure 2A shows
that leukocyte-type 12-LOX (L-12LOX) was expressed
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Fig. 3. Regulation of platelet type 12-
lipoxygenase (P-12LOX) expression in mouse
distal convoluted tubule (mDCT) cells. (A)
Expression levels of P-12LOX mRNA with
different treatments at 3 hours and 24
hours. GAPDH was amplified to standard-
ize for the amount of RNA subjected to re-
verse transcription. Values are mean ± SEM
(N = 5 different cultures) of densitometry
arbitrary units. A representative gel with P-
12LOX band (lower) and GAPDH house-
keeping band (upper) is shown. (B) Western
blot analysis with specific human P-12LOX
antiserum shows a band of 75 kD. Preliminary
7.5% SDS-polyacrylamide gels were run and
were stained with Coomassie blue to confirm
equality of loading in each lane.
in the kidney in addition to in other tissues (Fig. 2A, upper
panel). The middle panel pictures an immunohistochem-
ical section of human kidney. It shows that the level of
expression of this enzyme is highest in the proximal and
distal tubules, and in the mesangium. The lower panel
shows an RT-PCR of mDCT cell mRNA, and demon-
strates that the mDCT cell line expressed the L-12LOX at
the basal, unstimulated level under the culture conditions
employed. With respect to platelet-12-LOX (P-12LOX),
Figure 2B shows that this isoform was expressed in the
kidney in addition to other tissues. Immunohistochemical
analysis demonstrated that, while it was also expressed in
tubules and mesangium, stronger staining was obtained
at the level of distal tubules (Fig. 2B, middle panel). As
occurred with L-12LOX, mDCT cells expressed the P-12-
LOX isoform in resting conditions (Fig. 2B, lower panel).
Hormonal regulation of P-12LOX in mDCT cells
Figure 3 depicts the results of hormonal treatments on
P-12LOX mRNA and protein levels. There were no dif-
ferences in the expression level of P-12LOX mRNA in
response to any of the different hormones tested at 3, 9,
or 24 hours. At 3 hours, the means (in arbitrary units)
were: vehicle 2.04 ± 0.15, ALDO 2.17 ± 0.18, 8Br-cAMP
1.97 ± 0.25, ANG II 1.84 ± 0.15, and combined treat-
ments 2.1 ± 0.28 (P = ns); at 24 hours: vehicle 2.17 ±
0.11, ALDO 2.22 ± 0.25, 8Br-cAMP 2.10 ± 0.17, ANG II
1.99 ± 0.13, and combined treatments 2.43 ± 0.23 (P =
ns). This lack of effect was also observed at 9 hours (data
not shown). Further, we analyzed the expression of P-
12LOX protein under the different stimuli. As Figure 3B
shows, no significant differences within treatments were
detected.
Hormonal regulation of l-12LOX in mDCT cells
Figure 4 shows the effect of the different hormones on
L-12LOX mRNA and protein levels. As occurred with P-
12LOX, there were no differences in the expression level
of L-12LOX mRNA with any of the hormones compared
to the resting state at 3, 9, or 24 hours. At 3 hours, means
(in arbitrary units) were: vehicle 0.30 ± 0.04, ALDO
0.41 ± 0.06, 8Br-cAMP 0.35 ± 0.05, ANG II 0.32 ± 0.05,
and combined treatments 0.42 ± 0.05 (P = ns); at 24
hours: vehicle 0.47 ± 0.09, ALDO 0.43 ± 0.08, 8Br-cAMP
2.10 ± 0.10, ANG II 1.99 ± 0.05, and combined treatments
2.43 ± 0.05 (P = ns). The lack of effect on RNA expres-
sion levels was also observed at 9 hours (data not shown).
Further, we analyzed L-12LOX protein levels under the
different stimuli. As Figure 4B shows, no significant dif-
ferences were detected.
Expression of the 12(R)-LOX and E-12LOX
To further characterize the expression of 12-LOX iso-
forms in mDCT, we determined the expression of 2
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Fig. 4. Regulation of leukocyte type 12
lipoxygenase (L-12LOX) expression in mouse
distal convoluted tubule (mDCT) cells. (A)
Expression levels of L-12LOX mRNA with
different treatments at 3 hours and 24
hours. GAPDH was amplified to standard-
ize for the amount of RNA subjected to re-
verse transcription. Values are mean ± SEM
(N = 5 different cultures) of densitom-
etry arbitrary units. A representative gel
with L-12LOX band (lower) and GAPDH
housekeeping band (upper) is shown. (B)
Western blot analysis with specific L-12LOX
antiserum shows a band of 75 kD. Preliminary
7.5% SDS-polyacrylamide gels were run and
were stained with Coomassie blue to confirm
equality of loading in each lane.
recently cloned isoforms using RT-PCR with specific
primers against mouse E-12LOX and 12(R)-LOX (see
Table 1). As shown in Figure 5A, we detected the expres-
sion of the 12(R)-LOX. On the contrary, E-12LOX was
not expressed in mDCT (data not shown). We further
tested if 12(R)-LOX was responsive to hormones at the
mRNA level. As depicted in Figure 5B, none of the stim-
uli employed significantly changed the mRNA levels of
this enzyme. At 3 hours, means (in arbitrary units) were:
vehicle 1.41 ± 0.12, ALDO 1.24 ± 0.14, 8Br-cAMP 1.13 ±
0.08, ANG II 1.12 ± 0.17, and combined treatments
0.97 ± 0.08 (P = ns); at 9 hours: vehicle 0.91 ± 0.08,
ALDO 0.90±0.13, 8Br-cAMP 1.09±0.13, ANG II 1.02±
0.09, and combined treatments 0.99 ± 0.12 (P = ns). The
lack of effect on RNA expression levels was also observed
at 9 hours (data not shown).
Basal and stimulated 12(S)-HETE production by
mDCT cells
Mouse DCT cells in culture produced 12-(S)-
HETE, as shown in Figure 6. To further characterize
12(S)-LOX metabolism in mDCT cells, we analyzed
12(S)-HETE production in response to aldosterone,
cAMP, vasopressin, and angiotensin II. As Figure 6 shows,
12(S)-HETE production was enhanced by cAMP or vaso-
pressin treatment. At 2 hours, means in pg/106cells were:
vehicle 42.1 ± 6.7, ALDO 58.1 ± 11.0 (P = ns); 8Br-cAMP
96.9 ± 7.6 (P ≤ 0.01 vs. vehicle), ANG II 52.4 ± 11.9
(P = ns), and AVP 76.1 ± 11.5 (P ≤ 0.02 vs. vehicle)
(N = 9). At 6 hours of treatment, means were vehicle
47.7 ± 9.3, ALDO 63.1 ± 9.6 (P = ns), 8Br-cAMP 119.6 ±
17.6 (P ≤ 0.01 vs. vehicle), ANG II 63.7 ± 11.7 (P = ns),
and AVP 90.2 ± 8.7 (P ≤ 0.02 vs. vehicle) (N = 9). As de-
tailed above, the AVP and 8Br-cAMP-increases in 12(S)-
HETE is independent of changes in mRNA or protein
expression. Unlike what occurs in mesangial or vascu-
lar smooth muscle cells, angiotensin II did not enhance
12-HETE production in mDCT cells. Since the mDCT
cell line expresses AT1a receptors (but not ATb or AT2
receptors), we further evaluated the angiotensin II re-
sponsiveness of this cell line by measuring the production
of TGF-b . Treatment of mDCT with angiotensin II did
in fact increase supernatant levels of this cytokine (basal
0.83 ± 0.04; stimulated 1.27 ± 0.14 pg/mL, P < 0.05).
DISCUSSION
This study reports the presence of an active and
cAMP-regulated 12LOX metabolism in mDCT. In this
sense, we have detected the expression of P-12LOX and
L-12LOX at the molecular level in this cell line. More-
over, we have found expression of these LOX isoforms at
the distal tubules in vivo. Stimulation of cells with cAMP
enhanced the production of 12(S)-HETE, an effect that
was independent of changes in mRNA or protein lev-
els of LOX isoforms. On the contrary, aldosterone and
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Fig. 5. Expression and regulation of 12 R
lipoxygenase (12(R)-LOX) in mouse distal
convoluted tubule (mDCT) cells. (A) Shows
the expression of 12(R)-LOX gene in mDCT
cells and in mouse kidney mRNA. (B) Ex-
pression levels of 12(R)-LOX mRNA with
different treatments at 3 hours and 9 hours.
GAPDH was amplified to standardize for the
amount of RNA subjected to reverse tran-
scription. Values are mean ± SEM (N =
5) of densitometry arbitrary units. A repre-
sentative gel with 12(R)-LOX band (lower)
and GAPDH housekeeping band (upper) is
shown.
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Fig. 6. 12(S)-HETE production in mouse distal convoluted tubule
(mDCT) cells. 12-LOX activity in mDCT cells was determined by mea-
suring 12(S)-HETE supernatant levels in the basal state (vehicle =
VEH; 0.03% ethanol) and after different treatments. Aldo, aldosterone;
Ang II, angiotensin II; AVP, vasopressin. ∗P ≤ 0.02 vs. vehicle and ∗∗P ≤
0.01 vs. vehicle.
angiotensin II did not produce significant effects on 12-
LOX metabolism in mDCT.
Several studies have shown alterations in 12-LOX
metabolism in different hypertensive animal models
[10]. Moreover, the administration of LOX inhibitors,
phenidone and 5,8,11-eicosatriyonic acid, reduces blood
pressure in several rat models of hypertension, such as the
SHR and the 2 kidney, 1 clip renovascular hypertensive
rats [24]. This response to LO inhibition suggests a role
for LO metabolites in the pathogenesis of experimental
hypertension. Accordingly with this finding, we recently
described that urinary excretion and platelet production
of 12(S)-HETE was increased in patients with essential
hypertension, although its source (renal vs. systemic) was
not assessed [11]. The kidney appears to be an active site
of 12-LOX metabolism, mesangial and vascular smooth
muscle cells being the most frequently cell type studied
[12, 25]. Renal tubular cells have been shown to play cru-
cial roles in a number of pathophysiologic processes, such
as hypertension, and in the fibrogenic processes accom-
panying chronic renal disease [14, 26]. The immortalized
cell line of mouse DCT used in this study has been pre-
viously characterized at the molecular level with respect
to its responsiveness to several hormones, such as aldos-
terone, vasopressin, and cAMP [18–20]. Since 12-LOX
metabolism and regulation at the molecular level has not
purposely looked at renal tubular cells to date, our re-
sults are novel in several points. First, we show that both
P-12LOX and L-12LOX are expressed in proximal and
distal tubules, in addition to mesangial cells. L-12LOX
has been previously found expressed in mesangial cells
and vascular smooth muscle cells in the rat [12]. In con-
trast to our findings, in that previous study, only faint
and patchy staining of L12-LOX was found in proximal
and distal tubules. However, 12-HETE production has
been reported in cortical tubules preparations [27] and
in the proximal convoluted tubule, pointing to the renal
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tubules as an important source of 12-HETE [28]. To our
knowledge, no previous study has specifically reported
and focused on the expression of P-12LOX in the dis-
tal convoluted tubules. According to this localization in
immunohistochemistry studies, the mDCT cell line ex-
pressed both isoforms at the mRNA and protein levels.
Second, 12-LOX metabolism appears to be active
and hormonally regulated in mDCT cells. The DCT is
a hormonally regulated segment of the nephron, and
several hormones, such as aldosterone, vasopressin, and
angiotensin II, have been reported to exert important
effects at this level [29]. 12-HETE has been reported
as modulator of the actions of angiotensin II in vascu-
lar smooth muscle cells and adrenal cells [8, 30]. There-
fore, we evaluated the effects of hormones relevant to
DCT physiology on the level of expression of LOX and
the production of 12-HETE using the mDCT cell line.
For instance, whereas aldosterone or angiotensin II did
not affect 12-LOX activity in this cell model, the produc-
tion of 12(S)-HETE was significantly enhanced by vaso-
pressin and cAMP. The lack of effect of angiotensin II on
12-HETE production in mDCT contrast with its known
effects in vascular smooth muscle cells and in adrenal
cells [31, 32]. The mDCT cells expressed AT1a receptors,
but no expression of AT1b or AT2 receptors was found.
Angiotensin II–mediated induction of 12-LOX pathways
has been associated with both AT2 and AT1a receptor
activation, depending on the cell type [33, 34], and with
the activation of the p38-MAPK pathway [34]. While an-
giotensin II was not able to stimulate 12-HETE synthesis
in mDCT cells, it was able to increase the net production
of transforming growth factor b-1, pointing to an active
p38-MAPK pathway in these cells.
Vasopressin is known to modulate biologically rele-
vant P-450 metabolites in renal tubular cells, and to in-
crease the expression of Na transporters in the distal
nephron [35]. The effects of vasopressin on lipoxygenases
in tubular cells has previously not reported. In mDCT
cells, the vasopressin-enhanced 12(S)-HETE production
was mimicked by 8-Br-cAMP, a cell permeable analog of
cAMP, which is one of the known intracellular mediators
of AVP actions. These effects appear to be due to changes
in 12-LOX activity because they were observed without
changes in L-12LOX or P-12LOX mRNA or protein lev-
els. It has been previously described that 12(S)-HETE
inhibits adenylate cyclase in several cell types, thus re-
ducing the levels of cAMP [36]. Therefore, it is tempt-
ing to speculate that 12-HETE could act as a physiologic
negative feedback of vasopressin action in distal tubule
cells. There is a known similar negative feedback action
of protaglandins, since AVP-stimulated PGE1 has been
shown to counteract the increase in water permeability
induced by AVP in the cortical collecting duct [37]. Vaso-
pressin activates adenylate cyclase, and stimulates water
and sodium reabsorption in the distal nephron by up-
regulating aquaporins and the epithelial Na channels in
the distal nephron. In this scenario, the activation of 12-
LOX by vasopressin could act as a counter-regulatory
loop by inhibiting Na transport in this nephron segment.
In several works, 12-HETE has been shown to inhibit Na
transport [15, 38], and although this inhibition has been
explored only in the proximal tubule, it has been shown
to be mediated by activation of PKC, a kinase known to
inhibit Na transport both in proximal and distal nephron
[29].
The vascular (vasoconstriction) and tubular (inhibition
of Na transport) effects of 12(S)-HETE may affect blood
pressure in opposite directions, thus complicating the role
for this metabolite in hypertension. A similar example
can be found in another HETE compound, in this case
a P-450–derived metabolite. Specifically, 20-HETE has
been shown to be linked to various models of hyperten-
sion by genetic approaches, as well by expression stud-
ies and, like 12-HETE, has been demonstrated to be an
important vasoconstrictor of renal vessels (mediating an-
giotensin II), as well as an inhibitor of Na reabsorption
in the thick ascending limb of Henle [39].
CONCLUSION
We have provided evidence that distal convoluted cells
from mice have an active 12-LOX metabolism, with pro-
duction of 12(S)-HETE enhanced by stimulation by va-
sopressin or cAMP, suggesting a role for this eicosanoid
in the physiologic response of this tubular segment to
hormones.
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